

August 9, 2022
SymBio Pharmaceuticals Limited
Fuminori Yoshida
Representative Director
President and Chief Executive Officer
(Securities Code: 4582)

**The National Institute of Neurological Disorders and Stroke and SymBio
Pharmaceuticals Limited will collaborate to evaluate the potential antiviral activity of
brincidofovir (BCV) against Epstein Barr virus (EBV)**

TOKYO, Japan, August 8, 2022 -- SymBio Pharmaceuticals Limited (Headquarters: Tokyo, “the Company”) today announced that it has entered into a collaboration agreement (the “Agreement”) with the National Institute of Neurological Disorders and Stroke (“NINDS”), part of the National Institutes of Health (NIH) in the United States, for the transfer of materials for evaluation of BCV’s potential antiviral effect on Epstein Barr virus (EBV).

Under the Agreement, SymBio will transfer BCV IV to NINDS, who will conduct preclinical studies to evaluate BCV’s antiviral effect on EBV.

Statement from Mr. Fuminori Yoshida, President and CEO of SymBio: "Through this collaboration with NINDS, we hope that the high antiviral effect of BCV IV against the EB virus will help us to understand the possibility of intervening in the disease progression of multiple sclerosis by targeting the EB virus, which is a major cause of multiple sclerosis.

The Company does not expect the information presented herein to have any material impact on its financial outlook for the fiscal year ending December 31, 2022.

[Contact]

Investor Relations
Tel: +81 (0)3 5472 1125

About the anti-viral drug Brincidofovir

Brincidofovir (BCV) is a lipid conjugate of cidofovir (CDV). CDV is an antiviral drug already approved and marketed in the United States and the European Union, but unapproved in Japan. As BCV exhibits not only higher anti-viral activity, but also a superior safety profile in comparison with CDV, BCV is expected to be an effective treatment against a wide spectrum of dsDNA viruses such as herpesviruses such as cytomegalovirus (CMV), adenovirus (AdV), Epstein-Barr virus (EBV) and BK virus, papillomavirus. Moreover, BCV is an easy-to-use and novel highly active antimultiviral agent that can reduce the risk of nephrotoxicity, which is a serious side effect of CDV. SymBio entered into an exclusive global license agreement with Chimerix Inc. (Headquarters: Durham, NC, "Chimerix") for brincidofovir (BCV) on September 30, 2019. Under the terms of the agreement, Chimerix grants SymBio exclusive worldwide rights to develop, manufacture, and commercialize BCV in all human indications, excluding the prevention and treatment of orthopox infections (which includes smallpox and monkeypox). To develop global operations, the Company is considering partnerships that will utilize regional characteristics of the target diseases, and striving to maximize the business value of the products and to deliver to patients who need our products as soon as possible. The Company aims to serve the patients not only in Japan but also in Europe and the U.S. market where the market size for organ transplantation is large, and Asia, including the Chinese market.

About SymBio Pharmaceuticals Limited

SymBio Pharmaceuticals Limited was established in March 2005 by Fuminori Yoshida who previously served concurrently as Corporate VP of Amgen Inc. and founding President of Amgen Japan. In May 2016, the Company incorporated its wholly-owned subsidiary in the U.S., SymBio Pharma USA, Inc. (Headquarters: Durham, North Carolina, President: Carolyn Yanavich). The Company's underlying corporate mission is to "deliver hope to patients in need" as it aspires to be a leading global specialty biopharmaceutical company dedicated to addressing underserved medical needs.